A yearlong phase 3 trial shows elinzanetant can cut hot flashes by nearly three-quarters while maintaining a strong safety profile, positioning it as a promising new option for women seeking alternatives to hormone therapy.
Seeking commentary, including:
How might this drug help improve care for patients?